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Summary The gastrointestinal tract, with its rapid cell replacement, is sensitive to cytotoxic damage and can be a site of dose-limiting toxicity
in cancer therapy. Here, we have investigated the use of one growth modulator to manipulate the cell cycle status of gastrointestinal stem
cells before cytotoxic exposure to minimize damage to this normal tissue. Transforming growth factor beta-3 (TGF-,3), a known inhibitor of
cell cycle progression through G,, was used to alter intestinal crypt stem cell sensitivity before 12-16 Gy of gamma irradiation, which was
used as a model cytotoxic agent. Using a crypt microcolony assay as a measure of functional competence of gastrointestinal stem cells, it
was shown that the administration ofTGF-P3 over a 24-h period before irradiation increased the number of surviving crypts by four- to six-fold.
To test whether changes in crypt survival are reflected in the well-being of the animal, survival time analyses were performed. After 14.5 Gy
of radiation, only 35% of the animals survived within a period of about 12 days, while prior treatment with TGF-,B3 provided significant
protection against this early gastrointestinal animal death, with 95% of the treated animals surviving for greater than 30 days.
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Damage to the stem cells of renewing tissues is a serious adverse
side-effect of cancer therapy treatments. The moist stratified
epithelia (oral and genital) and the simple columnar epithelia in
the small bowel represent the most sensitive of these renewing
tissues. Damage to the stem cells in these sites results in a cellular
depletion which is manifested at times to be equivalent to the
transit time through the tissue. In murine small bowel, this is
equivalent to 3-4 days and in human oral mucosa to about 10 days.
We designed a series of experiments to investigate whether
transforming growth factor beta-3 (TGF-P3) could be used to
modulate the sensitivity of gastrointestinal stem cells. With the
increasing use of haematopoietic cytokines to combat myelosup-
pression (Morstyn et al, 1994), gastrointestinal and oral mucositis
are increasingly becoming dose- and schedule-limiting toxicities
in standard- and high-dose chemotherapy regimens. Chemo-
therapy agents that cause oral or gastrointestinal mucositis include
commonly prescribed agents, such as 5-fluorouracil (5-FU),
doxorubicin, vinblastine, methotrexate, taxol and etoposide. The
incidence of gastrointestinal mucositis is thought to be similar to
that of oral mucositis, which occurs in approximately 20-25% of
chemotherapy patients (Chabner, 1993).
The general principles of such experiments fall within the
outlines given below. An appropriate delivery of factors to
reversibly prevent cycle progression and cause an accumulation of
cells in G1 or Go before exposure to a cytotoxic agent may render
the stem cells more resistant. In this way, more stem cells might
Received 30 September 1996
Revised22 November 1996
Accepted29 November 1996
Correspondence to: CS Potten
survive the treatment and be present to initiate the regenerative
process. An alternative, or complementary, approach might be to
apply stimulatory factors that shorten the cell cycle following
exposure to a cytotoxic agent, on the principle that this might
speed up the regenerative process. Clearly, combinations of
inhibitors before cytotoxic exposure and stimulators after cyto-
toxic exposure might in theory represent the most effective
approach. It is interesting to note that, if the principles of the
experiment are valid, reversal of the sequence, i.e. stimulators
before or inhibitors after cytotoxic exposure, might be expected to
result not in protection but sensitization ofthe system.
TGF-js have been shown to reversibly inhibit the proliferation
of epithelial and haematopoietic progenitor cells in mid-late G,
phase (Polyak et al, 1994; Sherr and Roberts, 1995). Maximal inhi-
bition of cell cycling in unsynchronized cells requires thatTGF-P
be present for one cell cycle period (Geng and Weinberg, 1993). In
the prevention of chemotherapy- or radiotherapy-induced oral
mucositis, it is critical to optimize the length of time ofTGF-P3
exposure, given the evidence that TGF-f3 acts to protect cells by
reversible inhibition of cell growth (Sonis et al, 1994). Sufficient
preincubation with TGF-P3 is required to take cells out of cycle
both before and during exposure to chemotherapy while, ideally,
entry of cells back into cycle should occur as soon as the level of
chemotherapeutic drug drops below a toxic concentration.
We report here the results ofexperiments usingTGF-P3 admin-
istered before a range of doses of gamma rays on the survival of
intestinal stem cells. Stem cell function has been measured using
the crypt microcolony regeneration assay (Withers and Elkind,
1970; Potten and Hendry, 1985, 1995) over a range of gamma-ray
doses and by studying the survival time of animals receiving
high doses of radiation. The TGF-P3 was administered over
a protracted period of 24 h before the radiation exposure, and this
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treatment afforded very significant protection both within the
microcolony assay and on whole animal survival. The principles
of the experimental approach, outlined above, were tested by
reversing the sequence (i.e. TGF-,B3 after irradiation) in which
case sensitization was observed.
MATERIALS AND METHODS
Animal studies
BDF1 mice (Paterson Institute), aged 10-12 weeks and weighing
about 25 g, housed under conventional conditions with food and
water ad libitum and a 12-h light cycle (lights on at 0700 h) were
used throughout the experiment. For the crypt microcolony assay,
groups of six mice were treated at each dose. Control animals
received either radiation alone or saline with 0.1% bovine serum
albumin (BSA) (the vehicle forTGF-P3). For the animal survival
time studies, groups of 20 mice were used for each treatment
protocol. All experimental procedures were conducted in accor-
dance with the recommendations of the Animals (Scientific
Procedures) Act 1986, UK.
Irradiation methods
For the crypt microcolony assay, animals were irradiated in a
caesium-137 gamma irradiator at a dose rate of 3.5 Gray (Gy)
min-1 delivered whole-body to animals breathing pumped air.
For the whole animal survival studies, anaesthetized animals
were irradiated with X-rays at 300 kVp (HVL 2.3 mm Cu) with the
thorax, forelegs and head shielded. The dose rate was
0.62 Gy min-'. We have shown that the crypt microcolony survival
curves generated using the caesium whole-body irradiation, anaes-
thetized partial-body X-rays and whole-body X-rays anaesthetized
or unanaesthetized were all essentially indistinguishable (Potten,
unpublished data). The peak in stem cell DNA synthetic activity in
the small intestine is observed at 03.00 h (Potten et al, 1977).
Radiation doses were all delivered at the same time of day
(03.00 h; making use ofa room where the light cycle was reversed
so that the radiation could be delivered at 15.00 h real time). The
animals were acclimatized to the reverse-cycle room for 2 weeks
before an experiment.
Production, isolation and use of recombinant TGF-,3
Recombinant TGF-P3 was prepared either by purification of
conditioned media from CMV/TGF-,B3-transfected Chinese
hamsterovary (CHO) cells (Stewart et al, 1996) orby the refolding
and dimerization of TGF-P3 monomer expressed in
E. coli, according to the method of Schlunegger et al (1992). Both
TGF-P3 preparations demonstrated the same specific activity in
vitro (IC50 35 pg ml-'; data not shown) using a standard CCL64
growth inhibition assay (Iwata et al, 1985).
The TGF-03 was dissolved in saline with 0.1% BSA and was
delivered intraperitoneally (i.p.) at doses between 0.5 and 10 ,ug
per mouse, per injection, with the majority of the experiments
using a dose of 2.5 gg per mouse. A dose of 2.5 jg per mouse is
equivalent on a weight basis to 100 jg kg-'. The injection proto-
cols generally involved four injections at 24 h, 8 h, 4 h before
exposure to ionizing radiation and 0 h with 0 being immediately
after irradiation. This represented the standard delivery protocol.
Various alternative injection protocols were also investigated
(-24, -16, -8, -4 and 0 h), ranging through to protocols in which
TGF-,3 was delivered following a dose of radiation. Specifically,
other protocol tests were: -32, -24, -8, -4, 0; -24, -8, -4, 0, +4;
and +8, +16, +24, +32 h, where + indicates the time after irradia-
tion and - indicates the time before irradiation.
Crypt microcolony assay
The crypt microcolony assay (Withers and Elkind, 1970) is gener-
ally accepted as being a test ofthe functional capacity ofintestinal
stem cells to regenerate and maintain the intestinal epithelium. It
has been described extensively and used widely (Potten et al,
1983). Briefly, it involves fixation of the entire intestine 3-4 days
after radiation and the preparation of routine 3- to 5-jim paraffin
sections stained with haematoxylin and eosin, cut transversely to
the long axis of the intestine. This will generate cross-sections of
the intestine, the perimeter or circumference ofeach cross-section
representing a unit of length within which the number of crypts
can be counted. Each cryptis a closedproliferative unit maintained
by a number of stem cells that possess the ability to regenerate the
crypt by a process of clonal growth and hence have been termed
clonogenic cells. A crypt cannot be repopulated by cells from
outside the crypt. Each experimental group contained six mice.
From each mouse ten cross-sections were obtained and the number
of regenerating crypts was counted 3-4 days after irradiation.
Thus, for each experimental group, 60 cross-sections were scored.
As the probability ofobserving a regenerating crypt in a section is
dependent on the size of the structure, and this may vary between
different treatment groups, the size of 15 representative crypts was
measured at their widest point and a size correction was applied to
the data (Potten et al, 1981). For several of the experiments, a
range of irradiation doses was studied and hence survival curves
for crypts could be generated. Data for individual mice are
presented on the graphs. The DR FITprogram (Roberts, 1990) was
used with a multitarget model for fitting lines to such curves, for
determining the parameters that define the curves with their confi-
dence intervals, and for tests ofstatistical difference between indi-
vidual curves using variance-ratio F-tests. A significance level of
0.05 was used.
Survival time experiments
Groups of 20 mice were partial-body irradiated with TGF-f3
administration or saline/BSA before the irradiation according to
the standard protocol. The mice were examined four times a day
for their health status; any moribund animals were sacrificed and
any deaths recorded.
RESULTS
Using five different radiation doses between 12 and 16 Gy, the
number ofsurviving crypts decreased exponentially with increasing
dose, as shown by Figure 1. There was no statistically significant
difference between the survival curve obtained with radiation alone
and that generated by prior injections of saline/BSA. The Do value
defining the radiation alone curve is 119.3 ± 17.2 cGy and the
extrapolation number N is 3115 ± 4784. The Do is a measure of
radiosensitivity and is the reciprocal ofthe slope ofthe exponential
part of the curve. For the saline/BSA groups, the corresponding
figures areDo = 112± 8.1 cGy andN = 5093± 4154.
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Figure 1 Intestinal crypt survival curves for animals irradiated with no other
manipulations (0) and animals irradiated with a series of pre-irradiation
injections of saline/BSA at -24, -16, -8, -4 and 0 h (0). Each point
represents the data from an individual mouse and there were six mice at
each dose for each treatment protocol. Lines have been fitted using the Puck
formulation in the DR FIT program (Roberts, 1990). No significant difference
between the two sets of data was observed (P = 0.1783)
As shown in Figure 2, four injections ofTGF-,3 administered at
-24, -8, -4 h and immediately prior to a dose ofradiation results in
a survival curve that shows a highly significant shift (P < 0.00001)
to the right when compared with the curve for saline pretreatment,
indicative ofincreased resistance, i.e. protection ofthe clonogenic
stem cells by the prior treatment withTGF-03. The parameters that
define theTGF-P3 curves areDo = 127.7 ± 10.6 cGy andN = 4639
± 3866. The addition of an extra dose ofTGF-P3 16 h before the
irradiation, i.e. a protocol involving five doses ofTGF- 3 afforded
similar levels of stem cell protection (Figure 3). The curve is
highly significantly different from the saline/BSA curve
(P < 0.00001), and the parameters that define the TGF-P3 curve
areDo = 146.3 ± 13.7 cGy, N= 11299 + 1080. Figure 4 shows that
there is no statistically significant difference between the two
modes ofadministration ofTGF-P3 (four doses v five doses).
Table 1 shows the levels of protection afforded by the TGF-P3
at each individual dose, expressed as the ratio (protection factor) of
the levels of surviving crypts in theTGF-P3 group compared with
the saline/BSA vehicle group. Also shown are examples for which
individual doses have been repeated more than once. The effect of
increasingTGF-P3 dose perinjection on radiation damage induced
by 14 Gy radiation is shown in Table 2. An increase in crypt cell
protection from 3.3 to 5.4 as the dose of TGF-P3 was increased
from 0.5 to 10 gg per injection was observed. Table 3 shows the
effect of varying the injection regimens using a standard dose per
injection of 2.5 ,ug. The important observation from this experi-
ment is that TGF-,3 administration after irradiation decreases the
protective effect. A single injection 4 h after irradiation with the stan-
dard administration before irradiation reduces the protection factor
Figure 2 Intestinal crypts survival curves for animals pretreated with
saline/BSA (-) with five injections (protocol according to Figure 1) or
pretreated with four injections of 2.5 9g of TGF-f3 (U) at-24, -8, -4 and
0 h. A significant difference between the two survival curves was observed
(P < 0.00001)
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Figure 3 Intestinal crypt survival curves for animals pretreated with
saline/BSA (five injections, protocol as Figure 1; (0) and five injections of
TGF-,3 (2.5 gg; *). A significant difference between the two curves was
observed (P< 0.00001)
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Figure 4 Intestinal crypt survival curves comparing the data shown in
Figures 2 and 3 for animals pretreated with either four (U) or five (0)
injections of 2.5 9g ofTGF-J3. The survival curves do not differ significantly
from each other (P = 0.8846)
from about 4 to 1.6. Administration ofTGF-P3 following radiation
in fact significantly sensitized the crypts to radiation damage.
Here, only a third of the crypts survived compared with the
saline/BSA controls.
To effectively reduce these complicating effects of oral and
haemopoietic damage, we shielded the head, thorax and forelimbs
ofthe animal in our survival time experiments. Figure 5A shows the
survival time for mice receiving 14.5 Gy with and without pretreat-
ment with TGF-f3. It can be seen that TGF-,3 almost completely
protects the mice from the effects of this dose of radiation. In the
absence of TGF-,3, approximately 65% of the animals will die.
Table 1 Intestinal crypt cell protection from y-ray irradiation by prior
treatment with TGF-J3
Dose Protection factor
(Gy) Five injections of TGF-l3 Four injections ofTGF-P3
12 2.94 2.94
13 3.15 3.33
6.00 5.88
14 4.87 3.84
4.41
15 5.14 4.00
16 5.67 2.33
The protection factor represents theTGF-03 group mean divided by the
saline/BSA group mean. A value of 4.0 means that four times more crypts
survived in the TGF-,B3-treated group. The five injection groups were
administered 2.5 9g TGF-P3 -24, -16, -8, -4, 0 h before irradiation, while
the four injection groups were administered 2.5 9g TGF-j3 -24, -8, -4, 0 h
before irradiation. Each number represents the ratio from a separate group of
six treated and six saline animals.
Table 2 The effect of TGF-f33 dose on crypt cell survival
Dose ofTGF-03 (gg) Protection factor
0.5 3.32
1.5 4.05
2.5 4.41
10 5.36
The ratios of the crypt survival values obtained in TGF-p3-treated animals
compared with those for saline/BSA-treated controls are presented. The
dose of TGF-133 per injection was varied. TGF-fi3 was injected at-24, -8, -4
and 0 h before exposure to 14 Gy of gamma rays. The crypt cell protection
ratio rose progressively with increasing dose.
Figure 5B shows that once the dose of radiation goes beyond a
critical value (here 16 Gy), the levels of damage are such that
TGF-,3 can no longer protect the gastrointestinal mucosa.
Although more crypts survived (see Figure 3), their numbers are
insufficient to maintain animal survival.
Table 3 Protection of intestinal crypt cells as a function ofTGF-P3 administration schedule
Protocol Crypts per Mean ± s.d. Width (gm) Size-corrected Protection
circumference crypts per circumference factor
-24,-8,-4,0 10.1, 17.0, 17.3, 6.4, 14.2 ± 7.8 37.4 11.9 3.84
28.4, 6.0
-24,-16,-8,-4,0 17.9, 40.1, 10.9, 10.6 19.9 ± 10.6 41.2 15.1 4.87
-32, -24,-8, -4, 0 15.9, 14.8, 10.8, 14.2, 14.6 ± 3.3 42.5 10.7 3.45
11.2, 20.7
-24, -8, -4, 0, +4 3.5, 5.6, 2.6, 7.1, 7.8, 7.0 5.6 ± 1.9 36.3 4.8 1.55
+8, +16, +24, +32 1.1, 0.7, 1.0, 1.7, 1.1, 1.2 1.1 ±0.3 34.6 1.0 0.32
14 Gy alone 0.7, 0.6, 3.5, 1.2, 2.3, 5.3 2.4 ± 1.7 38.8 1.8
Untreated animals 93.6, 107.2, 103.2, 99.4, 99.3 ± 4.7 31.2 99.3
97.0, 95.3
Saline/BSA at 5.8, 2.8, 6.8, 3.6, 3.8, 1.2 4.0 ± 1.9 40.5 3.1 1.0
-24,-16,-8, -4,0
TGF-P3 (2.5 ,ug) was administered by i.p. injection. The i- symbol denotes time (h) before irradiation (14 Gy in all cases) while the '+' symbol denotes time after
irradiation. '0 time' denotes injections delivered immediately after irradiation. Protection factor represents theTFG-P3 group mean divided by the saline/BSA
group mean. The individual mean values for the counts of surviving crypts for each mouse are shown together with the width measurements used for the size
correction (Potten et al, 1981).
British JournalofCancer(1997) 75(10), 1454-1459 0 Cancer Research Campaign 19971458 CS Potten etal
A
100
50
0
10 20 30
Days after irradiation
B
100'
50
0
e Saline/BSA
10 20
Days
Figure 5 The survival time of animals exposed to 14.5 Gy (A) or 16 Gy (B)
of 300 kVp X-rays delivered to the abdomen. (A) Approximately 65% of the
animals pretreated with saline/BSA (-24, -8, -4, 0 h) died between days 3
and 12, while only 5% of the animals pretreated with TGF-03 succumbed to
the effects of radiation. Two animals in the TGF-j3 group died as a
consequence of the anaesthesia delivered at the time of irradiation and one
animal died between days 6 and 7. The data are presented in terms of
percentage survival. (B) Animal survival time data following a dose of 16 Gy
X-radiation (abdomen only). At this level of radiation dose and damage,
administration of TGF-f3 has no effect on animal survival
DISCUSSION
The transforming growth factor betas are potent inhibitors of cell
cycle progression in epithelial and haemopoietic systems. TGF-,3
acts, at least in part, through inhibition of cdk-/cyclin-dependent
kinase activity during the GI phase of the cell cycle (Polyak et al,
1994; Sherr and Roberts 1995). We have recently shown that
TGF-,B1 administered over a protracted period oftime can signifi-
cantly suppress the proliferative activity in the small intestinal
crypts, the effect being particularly pronounced in the stem cell
region (Potten et al, 1995). In addition, TGF-ps can have the oppo-
site effect on some cell types and act as indirect mitogens, particu-
larly for mesenchymal cell types, and exert effects on chemotaxis
and on the synthesis and degradation of extracellular matrix
proteins (Ignotz and Massague 1986; Posthlethwaite et al, 1987;
Wahl et al, 1987; Roberts and Sporn, 1991).
Here, we have shown that the propitious administration of
TGF-133 over a 24-h period before exposure to a cytotoxic agent
(radiation) can alter significantly the survival of the crypt stem
cells in vivo and increase overall animal survival. It is assumed
that this is achieved as a consequence of a reversible TGF-p3-
induced arrest of crypt stem cells cycling, thus rendering them
more resistant. TGF-fi1 or -2 has been shown to reversibly inhibit
proliferation of bone marrow stem cells and also to protect mice
from the effects of 5-FU over the period of 20-200 days
(Grzegorzewski et al, 1994). Our standard reference delivery
protocol involved four injections of 2.5 jg per injection per mouse
delivered 24 h preceding irradiation (-24, -8, -4, 0 h), with the
final injection being delivered immediately after the radiation
exposure. Subtle variations of this delivery regimen, by extending
the administration time or administering evenly spaced doses of
TGF-f33, had little effect on the levels of protection. Increasing the
dose per injection had a small beneficial effect. The administration
of some of the TGF-,3 injections after exposure to radiation abro-
gated the positive effect of TGF-,3 pretreatment. Administration
oftheTGF-P3 following irradiation resulted in a marked sensitiza-
tion. These data are consistent with the view that TGF-P33 was
inhibiting stem cell cycle progression, whereas continued dosing
after irradiation would be predicted to inhibit the regenerative
process.
The size of the crypts, as determined by their width measure-
ment, suggests that TGF-133 was affecting the overall cellularity.
Pretreatment with TGF-03 results in crypts 3-4 days after irradia-
tion that have a size slightly greater than observed in animals
pretreated with saline/BSA (Table 3). This would be expected if
the TGF-03 enabled extra stem cells to survive per crypt.
Continued cell cycle arrest by post-irradiation treatment with
TGF-,3, as would be predicted, tended to result in slightly smaller
crypts, and this demonstrates the importance of the crypt size
correction process (Potten et al, 1981).
There are indications that the stem cells in the crypts show a
slightly stronger circadian rhythm than the majority of the crypt
cells and have their peak DNA synthetic activity centred around
03.00 h (Potten et al, 1977). It is also believed that the stem cells
have a cell cycle duration of approximately 24 h (Potten, 1995).
Thus, delivering TGF-,3 over a period of 24 h before a dose of
radiation delivered at 03.00 h might be expected to have the
maximum effect in preventing cells entering S, i.e. in reducing
the number of DNA synthesizing cells in the stem cell compart-
ment at the time of irradiation. It remains to be seen whether
other protocols with different spacings between the TGF-,3
injections might be more effective. The current experiments, in
which the radiation was delivered at 03.00 h, resulted in better
levels of protection than were observed in earlier preliminary
experiments in which the time ofirradiation tended to be between
09.00 and 12.00h.
The well-being ofthe animal, and similarly ofa patient under-
going cancer therapy treatment, will depend on the competitive
interaction between cellular depletion processes and cellular
regeneration processes in the gastrointestinal tract. Ifthe former
are too severe, or the latter too slow, the consequence is loss of
mucosal integrity, which ultimately results in the symptoms of
the gastrointestinal radiation syndrome. If these symptoms are
too severe, the animal will die from gastrointestinal damage, and
this characteristically occurs over the period ofabout days 4-12.
The survival of intestinal crypts is determined by the level of
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survival of individual clonogenic stem cells within each crypt.
The survival and well-being ofthe animal depends ultimately on
the levels of surviving crypts (Hendry et al, 1983).
Following whole-body irradiation, survival of animals is influ-
enced in a complicated fashion by damage induced in the oral
mucosae and in the haemopoietic system. The latter is inherently
more sensitive than the gastrointestinal tract. Deaths attributed to
bone marrow damage usually occur later than 12 days. In order to
reduce the consequences ofthis oral andhaemopoietic damage, we
chose to irradiate only the abdomens ofthe animals in the survival
study. The survival time experiment was used as a paradigm for
patient well-being in a cancer treatment situation, and these exper-
iments can be viewed independently of the crypt survival studies.
However, the survival curves shown in Figures 2 and 3 show that
TGF-P3 can have a fairly dramatic effect on the fraction ofcrypts
surviving. The TGF-,B3 treatment effectively prevents damage
equivalent to 2 Gy ofradiation, and the consequences of this can
be seen very dramatically in the survival time study illustrated in
Figure SA - in the absence ofTGF-j3 65% ofthe animals die after
14.5 Gy, while in the TGF-,B3-treated group only 5% die. If the
dose is raised to 16 Gy, only about 0.5% of the crypts survive in
the absence of TGF-P3 (Figure 1). TGF-P3, may in principle,
protect some clonogenic cells and raise this to about 2.5%, but this
is still at a level ofdamage thatresults in animal death (Figure 5B).
The principles of these experiments may have major clinical
implications in terms oftheirpotential forimproving the quality of
life of cancer therapy patients. Furthermore, they may possibly
offer the opportunity ofdose escalation and, hence, improvements
in cure rate. However, there are many questions still to be
resolved. We have chosen to use radiation as a model cytotoxic for
which the dose and dose distribution can be fairly precisely
controlled. We need to demonstrate that TGF-i3 can protect the
intestinal epithelium against other forms of cytotoxic agents.
Cancer chemotherapy involves the use of multiple agents deliv-
ered repeatedly over a protracted period. There are no adequate
animal models for such combination therapies. We are currently
developing such models and the efficacy of TGF-,3 treatment
within this context needs to be tested. Finally, there is the question
of to what extent cells in tumours may be protected by TGF-j3
along with the normal tissue. Although this is not fully resolved,
there is strong evidence indicating that tumour cells are less
responsive to the cell cycle progression inhibition of TGF-i3
by abrogation of the signalling pathways, leading to the phospho-
rylation of the retinoblastoma (Rb) gene product (Sherr and
Roberts 1995).
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